{"id":"asc41","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By activating the thyroid hormone receptor beta, ASC41 enhances the expression of genes involved in lipid metabolism, potentially reducing levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides.","oneSentence":"ASC41 is a thyroid hormone receptor beta (THRβ) agonist that modulates lipid metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:55:05.837Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-alcoholic steatohepatitis (NASH)"},{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT05462353","phase":"PHASE2","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gannex Pharma Co., Ltd.","startDate":"2022-09-30","conditions":"Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis","enrollment":183},{"nctId":"NCT05118516","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Gannex Pharma Co., Ltd.","startDate":"2021-11-01","conditions":"Healthy Volunteer","enrollment":8},{"nctId":"NCT05118360","phase":"PHASE2","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH","status":"WITHDRAWN","sponsor":"Gannex Pharma Co., Ltd.","startDate":"2023-12-01","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":""},{"nctId":"NCT04686994","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"Gannex Pharma Co., Ltd.","startDate":"2020-12-22","conditions":"Overweight and Obesity, NAFLD, Hyperlipidemia","enrollment":20},{"nctId":"NCT04845646","phase":"PHASE1","title":"DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.","status":"COMPLETED","sponsor":"Gannex Pharma Co., Ltd.","startDate":"2021-03-16","conditions":"Healthy, NAFLD","enrollment":24},{"nctId":"NCT04692025","phase":"PHASE1","title":"Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers","status":"COMPLETED","sponsor":"Gannex Pharma Co., Ltd.","startDate":"2020-12-27","conditions":"Healthy, NAFLD, Hyperlipidemia","enrollment":12},{"nctId":"NCT04527250","phase":"PHASE1","title":"A Study of the Relative Bioavailability of ASC41 in Healthy Subjects","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2020-09-16","conditions":"Healthy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ASC41","genericName":"ASC41","companyName":"Ascletis Pharmaceuticals Co., Ltd.","companyId":"ascletis-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASC41 is a thyroid hormone receptor beta (THRβ) agonist that modulates lipid metabolism. Used for Non-alcoholic steatohepatitis (NASH), Hypercholesterolemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}